Olanzapine augmentation of clozapine

Annals of Clinical Psychiatry

Volumn 10, Issue 3, 1998, Pages 113-115

  Gupta, Sanjay ^a,b   Sonnenberg, Steven J ^c   Frank, Bradford ^d  

^a SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^b Olean General Hospital   (United States)

^c Cattaraugus Co Mental Health Clinic   (United States)

^d WCA Hospital   (United States)

Author keywords

Augmentation; Clozapine; Olanzapine

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; ELECTROCONVULSIVE THERAPY; FEMALE; HALLUCINATION; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CLOZAPINE; DRUG INTERACTIONS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRENZEPINE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0031731209     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022350221192     Document Type: Article

References (5)

1. Meltzer HY: An overview of the mechanism of action of clozapine. J Clin Psychiatry 1994; 55 (Suppl B):47-52
2. Borison RL, Pathiraja AP, Diamond BI, Meibach RC: Risperidone: Clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992; 28:213-218
3. Gupta S, Masand P: Olanzapine: Review of its pharmacology and indications in clinical practice. Primary Psychiatry 1997; 4:73-82
4. Pilowsky LS, Busatto GF, Ell PJ, Murray RM, Verhoeff NPLG, Kerwin RW: Dopamine D-2 receptor occupancy invivo by the novel atypical antipsychotic clozapine-Al-123 IBZM single-photon emission tomography (SPECT) study. Lancet 1992; 340:199-203.
5. Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sigmundsson T, Ell PJ, Noria V, Kerwin RW: Dopamine D-2 receptor occupancy in-vivo by the novel atypical antipsychotic olanzapine-Al-123 IBZM single-photon emission tomography (SPECT) study. Psychopharmacology 1996; 124:148-153